Synthorx (NASDAQ:THOR) Issues Quarterly Earnings Results

Synthorx (NASDAQ:THOR) posted its earnings results on Thursday. The medical instruments supplier reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.03), Bloomberg Earnings reports.

Synthorx stock traded down $0.38 during midday trading on Friday, reaching $15.92. 45,086 shares of the company traded hands, compared to its average volume of 103,652. The stock has a market cap of $523.88 million and a price-to-earnings ratio of -2.42. The company’s 50 day simple moving average is $14.62. Synthorx has a 12 month low of $11.00 and a 12 month high of $23.53.

Several research firms have recently commented on THOR. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Synthorx in a research report on Wednesday, May 1st. Zacks Investment Research upgraded shares of Synthorx from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a report on Thursday, July 18th. Five investment analysts have rated the stock with a buy rating, Synthorx has an average rating of “Buy” and a consensus target price of $22.67.

About Synthorx

Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.

Recommended Story: Percentage Decliners

Earnings History for Synthorx (NASDAQ:THOR)

Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with's FREE daily email newsletter.